Eureka Therapeutics Competitors and Similar CompaniesClear all
Eureka Therapeutics's competitors and similar companies include Immatics, Viralytics, MABION and Lion TCR.
 Eureka Therapeutics Eureka Therapeutics is a biotechnology company focused on discovery of novel antibody immunotherapies for the treatment of cancer.
|  Immatics Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. |  Viralytics Viralytics is a biotechnology company focused on the development and commercialization of oncology immunotherapies. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. |  Lion TCR Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases. | |
Founding Date | Founding Date 2006 | Founding Date N/A | Founding Date 2006 | Founding Date 2007 | Founding Date N/A |
Type | Type Private | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | |||||
Locations | Locations Emeryville, US HQ | Locations Tübingen, DE HQ Frankfurt Am Main, DE München, DE Houston, US | Locations Sydney, AU HQ | Locations Konstantynów Łódzki, PL HQ | Locations Singapore, SG HQ Guangzhou, CN Singapore, SG Singapore, SG |
Employees | Employees 442% decrease | Employees 24215% increase | Employees N/A | Employees 95 | Employees N/A |
Valuation ($) | Valuation ($) N/A | Valuation ($) 1.1 b | Valuation ($) N/A | Valuation ($) 21.7 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €54m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) zł151.7m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods zł29.9m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €55.1m (FY, 2023) | Gross profit N/A | Gross profit zł122.3m (FY, 2023) | Gross profit N/A |
Net income | Net income N/A | Net income (€97m) (FY, 2023) | Net income N/A | Net income zł41.3m (FY, 2023) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 45m (almost 5 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 20m (almost 7 years ago) |
Total funding raised | Total funding raised $ 130.4m | Total funding raised $ 267.3m | Total funding raised $ 27m | Total funding raised N/A | Total funding raised $ 20m |
For sources of this data, please see the company profile
View Company Profiles
Immatics
HQ
Tübingen, DE
Employees
242↑ 15% increase
Immatics is a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer.
View companyViralytics
HQ
Sydney, AU
Viralytics is a biotechnology company focused on the development and commercialization of oncology immunotherapies.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View companyLion TCR
HQ
Singapore, SG
Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases.
View company